Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD)
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine whether genetic polymorphisms in drug transporters
were associated with the side effects of OROS-methylphenidate medication in attention
deficit/hyperactivity disorder(ADHD).